When Should You Submit a Registration Change for Overseas IVD Products?

When Should You Submit a Registration Change for Overseas IVD Products?

The need to submit a registration change for IVD products after overseas registration depends on the target country's definition and classification of 'significant changes.' Companies must first determine whether the change affects product safety, efficacy, or intended use. Changes such as test principle, key components, reaction system, software algorithm, intended use, and specimen type typically require submission. For non-significant changes like packaging size adjustments or non-critical raw material supplier replacements (with equivalence verification), some countries permit reporting in annual updates or periodic reports.

Key Considerations

The same change may be handled differently across countries. For example, under CE IVDR, a change assessment is required and may involve notified body review; for US FDA 510(k) products, a supplemental application is needed; GHWP member states such as China, South Korea, and Brazil often require pre-approval. Companies should establish a change management procedure that maps change classifications to target country regulations and prepare technical documents, performance validation, risk assessment, and clinical evaluation in advance.

Regulatory Logic for Determining Change

To determine if a change requires submission, follow these steps: First, confirm whether the target country regulates the product as a medical device. Second, assess the product risk class (e.g., high-risk like HIV tests require stricter review). Third, evaluate the registration pathway (e.g., 510(k) for US FDA, IVDR for EU). Fourth, check if existing data (e.g., performance reports, risk management documents) can be reused. Fifth, ensure technical files, performance validation, risk management, clinical evaluation, labeling, and local agent information cover the change scope. If not, initiate the change submission.

Required Documentation

When submitting a change, prepare the following: change description document detailing before/after differences; performance validation reports covering analytical and clinical performance; risk management documents updated per ISO 14971; clinical evaluation reports if intended use or claims change; labeling drafts with changes highlighted; quality system documentation (e.g., ISO 13485); local agent/authorized representative information; and post-market surveillance data.

Common Mistakes

• Misclassifying a significant change as minor (e.g., adjusting incubation time or sample dilution).
• Assuming approval in one country suffices for another (e.g., US FDA approval does not exempt from Brazil ANVISA review).
• Implementing a change before regulatory approval, risking product recall or certificate revocation.
• Submitting incomplete documentation (e.g., missing original certificate, comparison tables, raw performance data).
• Neglecting local agent involvement—many countries require agent-submitted applications.
• Failing to document the rationale for the change, leading to regulatory queries.

Company Preparation Checklist

• [ ] Identify target country change classification guides (e.g., FDA 21 CFR 820.30, EU IVDR Annex IX, China NMPA regulations).
• [ ] Establish an internal change assessment process that aligns with target country regulations.
• [ ] Collect performance validation, stability, risk management, and clinical evidence, ensuring data meet applicable standards (e.g., CLSI, ISO 15189).
• [ ] Prepare labeling versions with before/after comparisons.
• [ ] Confirm local agent/authorized representative authorization and support.
• [ ] Update QM system documents: change control records, design change history, training records.
• [ ] Decide on direct submission or multi-country package (e.g., via MDSAP).
• [ ] Set project timelines considering review periods (e.g., US FDA 510(k) supplement typically 90–180 days; China NMPA second review 60 working days).

AIMEILI Perspective

From our regulatory consulting experience, the most commonly misjudged area is the classification of 'non-substantially equivalent' changes. Many companies believe that as long as performance validation shows no degradation, submission is unnecessary. However, US FDA and EU notified bodies explicitly require assessment of any change affecting safety or efficacy. We recommend creating a change classification matrix that lists each target country's definition of 'significant change' and compares it with your actual change. This helps avoid corrective actions due to misclassification. For document reuse, core evidence like analytical performance reports, risk management files, and ISO 13485 documentation can be reused across countries. However, clinical evaluations, labeling language, local regulatory declarations, and agent authorization letters must be localized. For example, EU IVDR requires clinical performance data from EU populations; if using Chinese data, supplementary validation is needed. Brazil ANVISA requires Portuguese labeling and a change assessment report from a local clinical trial institution. Regarding local agents and certificate control, change applications often need to be initiated by the agent. Companies should sign a change service agreement with the agent in advance to ensure uninterrupted service during the change period; otherwise, the registration certificate may lapse.

Frequently Asked Questions

Q: Can we continue selling the original product during the change application? A: It depends on local regulations. US FDA allows continued sale during the application if a new 510(k) or supplement has been submitted. Under EU IVDR, if the change is significant, the notified body may require suspension until approval. China NMPA requires that changes not be implemented before approval; otherwise, it is considered unlicensed production. Always check specific country regulations or consult your local agent.

Q: How should we handle the same change with different requirements across countries? A: Adopt a differentiated submission strategy. For example, changing the reagent bottle material to a more leak-proof type may be considered a minor change in China requiring only record-filing, while Brazil ANVISA may require performance revalidation. Prepare documentation per each country's requirements—do not substitute one country's approval for another. Create a multi-country change comparison table and prioritize countries with longer review cycles.

Q: Can we integrate documentation for multiple countries? A: Yes, but tailor each country's unique requirements. For instance, clinical evaluation should consider target population differences; labeling must be in the local language; risk management must comply with ISO 14971 and include local use scenarios. Use a standardized change template for common parts and attach country-specific sections as appendices. The MDSAP program allows unified reporting to participating countries (e.g., US, Canada, Japan, Brazil, Australia), improving efficiency.

Source: Compiled from AIMEILI Registration Practice Database, Medical Device International Registration Knowledge Base, and public regulatory information. Specific projects should be based on the latest requirements of target country regulatory authorities and product documentation.